3,704 IDEXX Laboratories, Inc. $IDXX Shares Sold by Glenview Trust Co

Key Points

• Glenview Trust Co. reduced its IDEXX Laboratories stake by 17.1% in the third quarter, selling 3,704 shares and retaining 18,003 shares valued at approximately $9.4 million.
• Institutional ownership remains high at 87.84%, with several other investors increasing their positions, including Virginia Retirement Systems, which boosted its holdings by 36.8%.
• Analyst sentiment is positive overall, with an average rating of “Moderate Buy” and a consensus price target of $721.67; IDEXX also exceeded quarterly earnings and revenue expectations.

Glenview Trust Co cut its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 17.1% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 18,003 shares of the company's stock after selling 3,704 shares during the period. Glenview Trust Co's holdings in IDEXX Laboratories were worth $9,401,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. VIRGINIA RETIREMENT SYSTEMS ET Al boosted its holdings in IDEXX Laboratories by 36.8% in the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 126,164 shares of the company's stock valued at $65,882,000 after purchasing an additional 33,946 shares during the period. Crystal Rock Capital Management increased its holdings in shares of IDEXX Laboratories by 6.4% during the third quarter. Crystal Rock Capital Management now owns 11,275 shares of the company's stock worth $5,888,000 after purchasing an additional 675 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in shares of IDEXX Laboratories by 10.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 3,015 shares of the company's stock worth $1,608,000 after purchasing an additional 280 shares during the period. BOKF NA increased its holdings in shares of IDEXX Laboratories by 9.1% during the third quarter. BOKF NA now owns 3,453 shares of the company's stock worth $1,803,000 after purchasing an additional 289 shares during the period. Finally, Motley Fool Asset Management LLC raised its position in shares of IDEXX Laboratories by 1.2% in the third quarter. Motley Fool Asset Management LLC now owns 6,988 shares of the company's stock valued at $3,649,000 after buying an additional 83 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

IDXX has been the subject of several recent research reports. UBS Group cut their price target on IDEXX Laboratories from $670.00 to $627.00 and set a "neutral" rating for the company in a research note on Tuesday. Weiss Ratings upgraded IDEXX Laboratories from a "hold (c)" rating to a "hold (c+)" rating in a research note on Thursday, October 8th. The Goldman Sachs Group began coverage on IDEXX Laboratories in a research note on Friday, October 16th. They set a "buy" rating and a $740.00 price objective on the stock. Citigroup lifted their price objective on IDEXX Laboratories from $650.00 to $670.00 and gave the company a "neutral" rating in a report on Wednesday, August 5th. Finally, BTIG Research dropped coverage on IDEXX Laboratories in a research report on Friday. They set a "buy" rating for the company. Eight research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $721.67.

Insider Buying and Selling

In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of the business's stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the completion of the transaction, the director owned 9,568 shares of the company's stock, valued at approximately $5,090,941.44. The trade was a 18.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.79% of the company's stock.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $551.21 on Friday. The company has a 50 day moving average of $534.27 and a 200-day moving average of $574.09. IDEXX Laboratories, Inc. has a 1-year low of $500.61 and a 1-year high of $769.98. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The company has a market cap of $43.42 billion, a PE ratio of 38.76 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The business had revenue of $1.22 billion for the quarter, compared to analysts' expectations of $1.20 billion. During the same period last year, the firm posted $3.50 earnings per share. The firm's quarterly revenue was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, equities research analysts forecast that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc NASDAQ: IDXX develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX's companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.